NCT05511623 2023-09-11Tislelizumab Combined With Concurrent Chemoradiotherapy as First-line Treatment for Stage IIIC2 Cervical CancerFirst Affiliated Hospital of Guangxi Medical UniversityPhase 2 Recruiting112 enrolled